SPK-7001 - Roche
Spark Therapeutics: Annual Report 2015 (Spark Therapeutics) - Mar 19, 2016 - Anticipated expiry of patent in US related to plasmid used in manufacture of SPK-CHM in 2032 
Anticipated patent expiry • Inherited Retinal Dystrophy • Ophthalmology
http://ir.sparktx.com/phoenix.zhtml?c=253900&p=irol-sec
 
Mar 19, 2016
 
.